Anzeige
Mehr »
Dienstag, 22.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
155 Leser
Artikel bewerten:
(1)

neurocare group AG Welcomes Simon Hörauf as Chief Platform Officer

The company is pleased to announce the appointment of Simon Hörauf as Chief Platform Officer, effective July 2025.

MUNICH, DE / ACCESS Newswire / July 22, 2025 / neurocare group AG ("neurocare" or the "Company"), a best practice platform for mental health and performance, is pleased to announce the appointment of Simon Hörauf as Chief Platform Officer of the company, effective July 2025.

Simon has advised neurocare on brand and product design since 2019 and stepped into the role of Chie

Simon has advised neurocare on brand and product design since 2019 and stepped into the role of Chie

Simon Hörauf is a design leader with more than 25 years of experience across brand and product domains. He has helped diverse organizations-from startups to federal agencies and global brands like Porsche, Qantas, BMW, Spotify, Mini, C&A, and The Green Party-craft successful products, compelling brands, and high-performing teams for the digital economy.

Simon has advised neurocare on brand and product design since 2019 and stepped into the role of Chief Platform Officer in July 2025. Before that, he led digital business strategy at Zeichen & Wunder and was Managing Partner at moodley, where he drove international expansion and service innovation. In Australia, Simon founded and led PLAY Communications - the country's most awarded experience marketing agency-which he sold to WPP in 2012. His career began in the early 2000s with the launch of Australia's first design festival, Sydney Esquisse. Simon has lived and worked in Germany, the UK, and Australia.

As Chief Platform Officer, Simon will strengthen neurocare to become a leading brand in mental health by strategically designing and developing neurocare's best practice platform, uniting hardware, digital solutions, and education into a user-focused offering. His key focus areas will include driving the development of user-centred product features and services, aligning and inspiring teams, processes and users, and unlocking marketing and sales synergies to grow the customer base and boost conversions.?

"Simon's appointment as Chief Platform Officer marks a significant milestone for neurocare as we continue to innovate and expand our impact on mental health globally," said Thomas Mechtersheimer, Founder & CEO of neurocare. "His deep understanding of design and strategy, combined with his passion for our mission, will be instrumental in driving growth and enhancing our platform. I am extremely excited to have Simon complete our global leadership team (GLT) and to drive our ambitious goals."?

"I am thrilled to join neurocare as Chief Platform Officer and to apply my experience to a brand and its products with so much potential to grow," said Simon Hörauf. "I am equally excited to help even more therapists and patients on their mental health journey."

About neurocare group AG

neurocare group has developed a best practice mental health platform, empowering clinicians to offer their patients, through personalized therapy, the best care for a variety of psychological or neurological conditions with more sustainable clinical outcomes. These therapy plans integrate innovative methods and tools, such as psychotherapy, neuromodulation and sleep hygiene, as well as medication. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing personalized therapy plans that improve self-regulation, resilience and social skills, while being cost-effective for the healthcare system.

The key technology elements of neurocare's platform are developed in-house, including leading TMS and EEG devices, a cloud-based software platform, as well as an online academy to give professionals the tools and neuroscientific understanding to properly apply these approaches in clinical practice.

neurocare's platform is currently applied throughout the company's own clinics across the US, the UK, the Netherlands and Australia, as well as in a growing number of third-party clinics.

Contact Information

Sally Remington
Global Marketing Manager
media@neurocaregroup.com
+49 152 2305 8385

.

SOURCE: neurocare group



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/neurocare-group-ag-welcomes-simon-h%c3%b6rauf-as-chief-platform-officer-1050620

© 2025 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.